Validade diagnóstica de biomarcadores na doença de Parkinson: revisão sistemática e meta-análise

Costa, Maria Fernanda Baeta Neves Alonso da; Reisdorfer, Emilene; Kempfer, Silvana Silveira; Fernandes, Gisele Cristina Manfrini; Porporatti, André Luís; Canto, Graziela De Luca

doi:10.1590/0034-7167-2017-0822

Acessibilidade / Reportar erro

Brasil

Revista Brasileira de Enfermagem

Español English

Brasil

Español English

sumário « anterior atual seguinte »

Sumário

REVISÃO • Rev. Bras. Enferm. 71 (6) • Nov-Dec 2018 • https://doi.org/10.1590/0034-7167-2017-0822 copiar

Validade diagnóstica de biomarcadores na doença de Parkinson: revisão sistemática e meta-análise

Autoria SCIMAGO INSTITUTIONS RANKINGS

RESUMO

Objetivo:

Identificar os biomarcadores para a doença de Parkinson, no líquido cefalorraquidiano, sangue, saliva e urina.

Método:

Os estudos foram coletados nas bases de dados Cochrane, LILACS, PubMed, SCOPUS, WEB OF SCIENCE, OpenGrey, ProQuest e Google Scholar, a partir de 3 de maio de 2016 e atualizados em 20 de março de 2017. Foram selecionados 22 estudos, avaliados pelo Quality Assessment Tool for Diagnostic Accuracy Studies e o Review Manager 5.3.

Resultados:

A evidência mostra que os anticorpos séricos podem ser usados como biomarcadores altamente específicos e precisos para o diagnóstico da doença de Parkinson em seu início. Os biomarcadores no líquido cefalorraquidiano estão relacionados ao aumento da severidade motora, à instabilidade postural, ao distúrbio da marcha e ao declínio cognitivo.

Conclusão:

Os anticorpos séricos e cefalorraquidianos podem ser utilizados como biomarcadores de diagnóstico no início da doença.

Descritores:
Revisão; Doença de Parkinson; Diagnóstico; Biomarcadores; Sangue

Autor	Amostra (N)	DP (n)	Controle (n)	Biomarcadores	Acurácia (%)	Sensibilidade (%)	Especificidade (%)
Aasly et al ⁽²³⁾23 Aasly JO, Johansen KK, Bronstad G, Waro BJ, Majbour NK, Varghese S, et al. Elevated levels of cerebrospinal fluid alpha-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers. Frontiers Aging Neurosci[Internet]. 2014[cited 2017 May 23];6:248. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4174885/pdf/fnagi-06-00248.pdf https://www.ncbi.nlm.nih.gov/pmc/article... (2014)				α-synuclein; o- α- synuclein; t-α- synuclein; LRRK2	α-synuclein: 74.00 o- α- synuclein: 79.00 t-α- synuclein; 64.00 LRRK2:66.00	α-synuclein: 65.00 o- α- synuclein: 73.00 t-α- synuclein; 53.00 LRRK2:63.00	α-synuclein:83.00 o- α- synuclein: 77.00 t-α- synuclein; 81.00 LRRK2:74.00
Aguiar et al ⁽¹³⁾13 Aguiar PMC, Severino P. Biomarkers in Parkinson Disease: global gene expression analysis in peripheral blood from patients with and without mutations in PARK2 and PARK8. Einstein[Internet]. 2010[cited 2017 May 23];8(3 Pt 1):291-7. Available from: http://apps.einstein.br/revista/arquivos/PDF/1674-Einsteinv8n3_pg291-7_eng.pdf http://apps.einstein.br/revista/arquivos... (2010)	15	10	5	PARK2 ou PARK8
Boll et al ⁽²²⁾22 Boll MC, Alcaraz-Zubeldia M, Montes S, Rios C. Free copper, ferroxidase and SOD1 activities, lipid peroxidation and NO(x) content in the CSF: a different marker profile in four neurodegenerative diseases. Neurochem Res[Internet]. 2008[cited 2017 May 28];33(9):1717-23. Available from: https://link.springer.com/article/10.1007%2Fs11064-008-9610-3 https://link.springer.com/article/10.100... (2008)	102	22	80	Cu/Zn-SOD; Lipid peroxidation assay; NOx; Celuloplasmin ferroxidase
Cao et al ⁽¹⁶⁾16 Cao XY, Lu JM, Zhao ZQ, Li MC, Lu T, An XS, Xue LJ. MicroRNA biomarkers of Parkinson's disease in serum exosome-like microvesicles. Neurosci Lett[Internet]. 2017[cited 2017 May 23];644:94-9. Available from: http://europepmc.org/abstract/med/28223160 http://europepmc.org/abstract/med/282231... (2017)	149	109	40	miR-24, mi R-30a-3p, mi R-30e-3p, miR-195, miR-223*, mi R-324-3p, mi R-331-5p, mi R-338-3p, miR-505, miR-626, miR- 15b, miR-16-2-3p, miR-19a, miR-19b, miR-29a, miR-29c, mi R-30c, miR-148b, miR-181a, miR-185, miR-221, mi R-339-5p, miR-450b-3p, and miR-1294	miR-19b, 0.75, (0.67–0.82); miR-24, 0,90 (0.85–0.94), and miR-195, 0.69 (0.61–0.77), miR-19b, miR-24 and miR-195. 0.94 (0.91–0.98).	miR-195, 82.6 miR-19b, 68.8 miR-24, 81.7 miR-19b, miR-24 and miR-195: 85.3.	miR-195, 55.0%, ; miR-19b, 77.5%; miR-24, 81.7%, miR-19b, miR-24 and miR-195: 90%
Ding et al ⁽⁵⁾5 Ding H, Huang Z, Chen M, Wang C, Chen X, Chen J, et al. Identification of a panel of five serum miRNAs as a biomarker for Parkinson's disease. Parkinsonism Relat Disord[Internet]. 2016[cited 2017 May 23];22:68-73. Available from: http://www.prd-journal.com/article/S1353-8020 (15)30038-9/pdf http://www.prd-journal.com/article/S1353... (2016)	197	106	91	hsa-miR-195 hsa-miR-15b hsa-miR-221 hsa-miR-181a hsa-miR-185	hsa-miR-195: 73.30 hsa-miR-15b: 89.70 hsa-miR-221: 85.40 hsa-miR-181a: 82.20 hsa-miR-185: 82.00	hsa-miR-195: 68.90 hsa-miR-15b: 76.90 hsa-miR-221: 75.80 hsa-miR-181a: 70.30 hsa-miR-185: 70.00	hsa-miR 195:75.80 hsa-miR 15b:86.80 hsa-miR 221:85.80 hsamiR181a:84.00 hsa-miR 185:83.00
Foulds et al ⁽²⁷⁾27 Foulds PG, Mitchell JD, Parker A, Turner R, Green G, Diggle P, et al. Phosphorylated alpha-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease. Faseb J[Internet]. 2011[cited 2017 May 23];25(12):4127-37. Available from: http://www.fasebj.org/content/25/12/4127.long http://www.fasebj.org/content/25/12/4127... (2011)	62	32	30	phospho- α-synuclein; α-synuclein; oligo- α-synuclein; oligo- phospho- α-synuclein	oligo- phospho- α-synuclein: 62	___	___
Foulds et al ⁽²⁾2 Foulds PG, Diggle P, Mitchell JD, Parker A, Hasegawa M, Masuda-Suzukake M, et al. A longitudinal study on alpha-synuclein in blood plasma as a biomarker for Parkinson's disease. Sci Rep[Internet]. 2013[cited 2017 May 28];3:2540. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3756331/pdf/srep02540.pdf https://www.ncbi.nlm.nih.gov/pmc/article... (2013)	280	189	91	phosphorylated α-synuclein;α-synuclein;	phosphorylated α-synuclein: 71.70 α-synuclein:55.80	___	___
Goldknopf et al ⁽²⁸⁾28 Goldknopf IL, Bryson JK, Strelets I, Quintero S, Sheta EA, Mosqueda M, et al. Abnormal serum concentrations of proteins in Parkinson's disease. Biochem Biophys Res Commun[Internet]. 2009[cited 2017 May 28];389(2):321-7. Available from: http://www.sciencedirect.com/science/article/pii/S0006291X09017392?via%3Dihub http://www.sciencedirect.com/science/art... (2009)	226	29 + 62	57 + 78	A. 57 Biomarkers; B. 21 Biomarkers		A. 57 Biomarkers: 96.40 B. 21 Biomarkers: 92.90	A. 57 Biomarkers: 93.30 B. 21 Biomarkers:93.30
Gorostidi et al ⁽²⁵⁾25 Gorostidi A, Bergareche A, Ruiz-Martinez J, Marti-Masso JF, Cruz M, Varghese S, et al. α-synuclein levels in blood plasma from LRRK2 mutation carriers. PLoS One[Internet]. 2012[cited 2017 May 28];7(12):e52312. Available from: http://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0052312&type=printable http://journals.plos.org/plosone/article... (2012)	275	166	109	LRRK2; α-synuclein; iPD		___	___
Grünblatt et al ⁽¹⁷⁾17 Grunblatt E, Zehetmayer S, Jacob CP, Muller T, Jost WH, Riederer P. Pilot study: peripheral biomarkers for diagnosing sporadic Parkinson's disease. J Neural Transm[Internet]. 2010[cited 2017 May 28];117(12):1387-93. Available from: https://link.springer.com/article/10.1007%2Fs00702-010-0509-1 https://link.springer.com/article/10.100... (2010)	139	105	34	PSMA2; LAMB2; ALDH1A1; HIST1H3E	PSMA2:87.20 LAMB2: 82.50 ALDH1A1:75.80 HIST1H3E: 72.00
Gui et al ⁽¹⁴⁾14 Gui Y, Liu H, Zhang L, Lv W, Hu X. Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease. Oncotarget[Internet]. 2015[cited 2017 May 28];6(35):37043-53. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741914/pdf/oncotarget-06-37043.pdf https://www.ncbi.nlm.nih.gov/pmc/article... (2015)	74	47	27	miR-1; miR-153; miR-409-3p; miR-19b-3p; miR-10^a-5p; miR153/mir-409-3p)	miR-1: 92.00 miR-153: 78.00 miR-409-3p: 97.00 miR-19b-3p: 70.50 miR-10a-5p: 90.00	miR-1: 94.00 miR-153: 93.00 miR-409-3p: 90.00 miR-19b-3p: 94.00 miR-10a-5p: 95.00	miR-1: 94.00 miR-153: 93.00 miR-409-3p: 90.00 miR-19b-3p: 94.00 miR-10a-5p: 95.00
Han et al ⁽²⁹⁾29 Han M, Nagele E, DeMarshall C, Acharya N, Nagele R. Diagnosis of Parkinson's disease based on disease-specific autoantibody profiles in human sera. PLoS One[Internet]. 2012[cited 2017 May 23];7(2):e32383. Available from: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0032383 http://journals.plos.org/plosone/article... (2012)	69	29	40	Autoantibody (10): NM_001544.2 NM_024754.2 BC051695.1 PHR5001 NM_006790.1 NM_032855.1 BC005858.1 NM_003141.2 BC094687.1 BC027617.1		93.10	100
Kang et al ⁽¹²⁾12 Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS, et al. Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol[Internet]. 2013[cited 2015 Jul 23];70(10):1277-87. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4034348/pdf/nihms573438.pdf https://www.ncbi.nlm.nih.gov/pmc/article... (2013)	102	63	39	Aβ1–42; Tau [T-tau]; [P-tau181]; α-synuclein		___	___
Karlsson et al ⁽²⁴⁾24 Karlsson MK, Sharma P, Aasly J, Toft M, Skogar O, Saebo S, et al. Found in transcription: accurate Parkinson's disease classification in peripheral blood. J Parkinsons Dis[Internet]. 2013[cited 2017 May 28];3(1):19-29. Available from: https://content.iospress.com/download/journal-of-parkinsons-disease/jpd120159?id=journal-of-parkinsons-disease%2Fjpd120159 https://content.iospress.com/download/jo... (2013)	154	79	75	α-synuclein (SNCA/PARK1/4); (PRKN/PARK2); L1 (UCHL-1/PARK5); (PINK1/PARK6); DJ-1 (DJ1/PARK7); (LRRK2/PARK8); (VPS35/PARK17); (EIF4G1/PARK18)
Khoo et al ⁽³⁰⁾30 Khoo SK, Petillo D, Kang UJ, Resau JH, Berryhill B, Linder J, et al. Plasma-based circulating MicroRNA biomarkers for Parkinson's disease. J Parkinsons Dis[Internet];2012[cited 2017 May 23];2(4):321-31. Available from: https://content.iospress.com/articles/journal-of-parkinsons-disease/jpd012144 https://content.iospress.com/articles/jo... (2012)	64	32	32	miR-626; miR-505; miR-222; k-TSP1; k- TSP2; k- TSP3; k-TSP4; k-TSP5; k-TSP1–5; k-TSP1–4; k-TSP1–3; k-TSP1,3,4		miR-626: 83.00 miR-505: 72.00 miR-222: 78.00 k-TSP1: 100.00 k- TSP2: 32.00 k- TSP3: 96.00 k-TSP4: 0.00 k-TSP5:0.00 k-TSP1–5: 96.00 k-TSP1–4: 96.00 k-TSP1–3: 96.00 k-TSP1,3,4: 96.00	miR-626: 100.00 miR-505: 97.00 miR-222: 73.00 k-TSP1: 56.00 k- TSP2: 00.00 k- TSP3: 9.00 k-TSP4: 100.00 k-TSP5:20.00 k-TSP1–5: 27.00 k-TSP1–4: 55.00 k-TSP1–3: 55.00 k-TSP1,3,4: 64.00
Margis et al ⁽¹⁰⁾10 Margis R, Rieder CR. Identification of blood microRNAs associated to Parkinsonis disease. J Biotechnol[Internet]. 2011[cited 2017 May 28];152(3):96-101. Available from: http://www.sciencedirect.com/science/article/pii/S0168165611000678?via%3Dihub http://www.sciencedirect.com/science/art... (2011)	16	8	8	miR-1; miR-22; miR 29a; miR-16-2; miR-26a2; miR-30a	___	___	___
Molochnikov et al ⁽¹⁸⁾18 Molochnikov L, Rabey JM, Dobronevsky E, Bonucelli U, Ceravolo R, Frosini D, et al. A molecular signature in blood identifies early Parkinson's disease. Mol Neurodegener[Internet]. 2012[cited 2017 May 28];7:26. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3424147/pdf/1750-1326-7-26.pdf https://www.ncbi.nlm.nih.gov/pmc/article... (2012)	156	92	64	SKP1A; HSPA8; PSMC4; ALDH1A1; HIP2
Park et al ⁽²¹⁾21 Park MJ, Cheon SM, Bae HR, Kim SH, Kim JW. Elevated Levels of a-Synuclein Oligomer in the Cerebrospinal Fluid of Drug-Naïve Patients with Parkinson's Disease. J Clin Neurol[Internet]. 2011[cited 2017 May 23];7(4):215-22. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3259496/pdf/jcn-7-215.pdf https://www.ncbi.nlm.nih.gov/pmc/article... (2011)	52	23	29	α- synuclein oligomer;Total α- synuclein	__	__	__
Parnetti et al ⁽¹⁹⁾19 Parnetti L, Farotti L, Eusebi P, Chiasserini D, De Carlo C, Giannandrea D, et al. Differential role of CSF alpha-synuclein species, tau, and A beta 42 in Parkinson's Disease. Frontiers Aging Neurosci[Internet]. 2014[cited 2017 May 28];6. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978246/pdf/fnagi-06-00053.pdf https://www.ncbi.nlm.nih.gov/pmc/article... (2014)	69	44	25	Aβ142/t-tau ratio; T-α- synuclein; O-α-synuclein; O/t-α-synuclein	Aβ42/t-tau ratio: 64.00 T-α-syn: 68.00 O-α-syn: 72.00 O/t-α-syn ratio: 78.00	Aβ42/t-tau ratio: 82.00 T-α-syn: 59.00 O-α-syn: 89.00 O/t-α-syn ratio: 82.00	Aβ42/t-tau ratio:56.00 T-α-syn: 80.00 O-α-syn: 48.00 O/t-α-syn ratio: 64.00
Tokuda et al ⁽²⁶⁾26 Tokuda T, Qureshi M, Ardah M, Varghese S, Shehab S, Kasai T, et al. Detection of elevated levels of a-synuclein oligomers in CSF from patients with Parkinson disease. Neurol[Internet]. 2010[cited 2017 May 28];75(20):1766-72. Available from:http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/665/CN-00772665/frame.html. http://onlinelibrary.wiley.com/o/cochran... (2010)	60	32	28	α-synuclein; oligo/total α- synuclein	α-synuclein: 85.90 oligo/total α- synuclein: 94,80	α-synuclein: 75.00 oligo/total α- synuclein: 89.30	α-synuclein: 87.50 oligo/total α- synuclein:90.60
Vivacqua et ⁽²⁰⁾20 Vivacqua G, Latorre A, Suppa A, Nardi M, Pietracupa S, Mancinelli R, et al. Abnormal Salivary Total and Oligomeric Alpha-Synuclein in Parkinson's Disease. Plos One[Internet]. 2016[cited 2017 May 23];11(3). Available from: http://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0151156&type=printable http://journals.plos.org/plosone/article... (2016)	100	60	40	α-synuclein; oligo/total α- synuclein	__	__	__
Wang et al ⁽¹⁵⁾15 Wang X, Yu S, Li F, Feng T. Detection of alpha-synuclein oligomers in red blood cells as a potential biomarker of Parkinson's disease. Neurosci Lett[Internet]. 2015[cited 2017 May 23];599:115-9. Available from: http://www.sciencedirect.com/science/article/pii/S0304394015003870?via%3Dihub http://www.sciencedirect.com/science/art... (2015)	202	100	102	α-synuclein; oligo/total α- synuclein	76.00	79.00	64.70

Associação Brasileira de Enfermagem SGA Norte Quadra 603 Conj. "B" - Av. L2 Norte 70830-102 Brasília, DF, Brasil, Tel.: (55 61) 3226-0653, Fax: (55 61) 3225-4473 - Brasília - DF - Brazil
E-mail: reben@abennacional.org.br

Acompanhe os números deste periódico no seu leitor de RSS

[1] AUTOR CORRESPONDENTE: Maria Fernanda Baeta Neves Alonso da Costa. E-mail: fernanda.baeta@ufsc.br